Visual Performance With Spatial Light Modulator

Visual Performance After Optically Correcting the Eye's Aberration With a Spatial Light Modulator

Eye's aberrations have been known to degrade human visual performance and the visual performance is significantly improved when correcting the aberrations in the central visual field. However, how the aberration correction affects the peripheral visual performance is not well understood. Moreover, how central and peripheral vision interacts remains unclear.

To conduct the study, we will use an adaptive optics vision simulator equipped with a Shack-Hartmann wavefront sensor and a spatial light modulator (see details in procedures section of the protocol). This system is capable of noninvasively controlling the eye's optical quality and evaluating visual performance simultaneously over a wide area of visual space. This study provides insights into the visual performance in the periphery visual field, and interaction between central and peripheral visual fields.

The goal of this study is to evaluate the visual performance at central and peripheral visual fields after correcting the ocular aberrations. An optical system equipped with a liquid crystal spatial light modulator will be used to achieve this goal non-invasively.

Study Overview

• Status: Not yet recruiting
• Conditions: Normal Healthy Eyes
• Intervention / Treatment: Device: Spatial light modulator

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Geunyoung Yoon, PhD; Phone Number: 7137437860; Email: gyoon2@central.uh.edu
• Study Contact Backup: Name: Jiakai Lyu, MS; Phone Number: 6262953929; Email: jlyu@central.uh.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

A person is eligible for inclusion in the study if he/she:

• Is between the ages of 18 and 60.
• Has normal corneas i.e. no corneal infections, no systemic pink eye, no clinically significant dry eye, and no corneal dystrophies.
• Has refractive errors less than +/- 10.0 Diopters in both eyes.

Exclusion Criteria:

A person will be excluded from the study if he/she:

• Adults between the ages of 18-60 who are unable to give informed consent
• Individuals below 18 years old
• Individuals above the age of 60
• Pregnant women (self-reporting, hormonal changes may alter the refractive status of the eye)
• Prisoners
• Students for whom you have direct access to/influence on grades
• People who do not understand or speak English
• Has clinically significant dry eye.
• Has clinically significant cataract.
• Has spherical refractive error that exceeds the limits outlined above.
• Is unable to hold his or her head steady for the duration of study measurements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: normal healthy group; Spatial light modulator	Device: Spatial light modulator; This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual acuity	Snellen "Tumbling E" method will be used to determine the smallest letter that a subject can see.	up to 6 separate sessions (each session taking up to 2 hours)
Contrast sensitivity	Light and dark sinusoidal stripes (Gabor gratings) will used to determine the smallest contrast that a subject can see	up to 6 separate sessions (each session taking up to 2 hours)
Contrast perception	Light and dark sinusoidal stripes (Gabor gratings) will used to determine differences in contrast perceived by the central and peripheral visual system	up to 6 separate sessions (each session taking up to 2 hours)

Collaborators and Investigators

• Sponsor: University of Houston

Study record dates

Study Major Dates

• Study Start (Anticipated): November 1, 2021
• Primary Completion (Anticipated): November 1, 2022
• Study Completion (Anticipated): March 1, 2023

Study Registration Dates

• First Submitted: November 11, 2021
• First Submitted That Met QC Criteria: November 23, 2021
• First Posted (Actual): November 26, 2021

Study Record Updates

• Last Update Posted (Actual): November 26, 2021
• Last Update Submitted That Met QC Criteria: November 23, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: STUDY00003209

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No